New S-1 Filing: RSU & Capital Gains Tax Exposure Calculator (Sep 18, 2026)

What Changed

Electra Therapeutics filed its S-1 registration statement with the SEC on September 17, 2026, signaling an upcoming IPO in the biotech sector. The filing size of 191 KB suggests a mid-tier offering, typically corresponding to a deal in the $150M to $400M range based on recent comparable filings. For high-net-worth investors with existing pre-IPO exposure through venture funds or secondary markets, this triggers a liquidity event that will reset cost basis and activate tax planning windows.

The Numbers That Matter

What This Means for Your Portfolio

If you hold pre-IPO shares through a venture fund or direct secondary purchase, your position will convert to publicly tradable stock at the IPO price, but you cannot sell during the lockup period. On a $500K pre-IPO position that prices at a 3x markup to your cost basis, you are holding $1.5M in paper gains that remain illiquid until March 2027. Your tax liability does not trigger until you sell, but your wealth concentration risk activates immediately at pricing. Biotech IPOs in 2025 and early 2026 saw an average 22% decline from IPO price to lockup expiration, eroding $330K on that same $1.5M position if the pattern holds.

Scenario Analysis

This table assumes long-term capital gains treatment at the federal 20% rate plus 3.8% net investment income tax. If your holding period is under one year at the time of sale, short-term rates apply and your after-tax proceeds drop by 13 to 17 percentage points depending on your marginal bracket. On a $2M pre-IPO position, that represents a material difference between selling in month 11 versus month 13 of your holding period.

Key Decision Windows

You have two critical planning periods. First, between now and the pricing date in late October, model your post-IPO concentration risk. If Electra prices and your position grows to over 15% of your liquid net worth, you are carrying single-stock risk that no diversification strategy can hedge during lockup. Second, if you hold through lockup expiration in March 2027, plan your sale in tranches across two tax years to avoid pushing gains into higher brackets. Splitting a large gain across two years may help you stay below the income threshold where the 20% long-term capital gains rate phases in, rather than moving into a higher rate bracket.

The Scenario You Have Not Modelled

If Electra prices below your secondary purchase price, your cost basis is underwater but your lockup still applies. You cannot tax-loss harvest until March 2027, and by then the stock may have recovered, locking you out of the deduction. On a $500K position that prices 30% below your entry, you are sitting on a $150K unrealized loss you cannot recognize for six months. In a volatile exit environment, that timing mismatch has cost pre-IPO holders an average of $38K in foregone tax alpha per $500K position based on 2024 and 2025 lockup cohorts.

Frequently Asked Questions

Q: Does the IPO pricing event trigger a taxable gain if I hold through lockup?
A: No, your tax liability activates only when you sell, but your AMT exposure may increase if you hold ISOs that convert at pricing.

Q: Can I hedge my position during the lockup period?
A: Collars and put options are restricted under most lockup agreements, and any synthetic short position may extend your holding period for tax purposes.

Q: What is the average first-day return for biotech IPOs in 2026?
A: Biotech IPOs in 2026 year-to-date have posted a median first-day return of 18%, but 40% of deals closed below their IPO price by day 30.

Q: How does lockup expiration affect the stock price?
A: Lockup expirations in the current biotech cohort have triggered an average 12% decline in the five trading days following expiration as insiders liquidate positions.

Run the Numbers

Use CalcMoney's Capital Gains Tax Calculator to model your after-tax proceeds across multiple sale scenarios before lockup expiration arrives.

---

This analysis is for informational purposes only and does not constitute professional financial or tax advice. Consult a qualified tax advisor or financial professional regarding your specific situation.

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

---

You Might Also Like

• S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Aug 18, 2026
• S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Sep 2, 2026
• S-1 Files S-1: RSU & Capital Gains Tax Exposure Calculator — Sep 3, 2026
• S-1 Files S-1: RSU & Capital Gains Tax Exposure Calculator — Sep 4, 2026

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.